The FIRST AND ONLY oral dual PI3K-δ and PI3K-γ inhibitor that predominantly targets malignant B cells and the tumor microenvironment1,2
COPIKTRA (duvelisib) is a kinase inhibitor indicated for the treatment of adult patients with1:
- Relapsed or refractory CLL or SLL after at least 2 prior therapies
- Relapsed or refractory FL after at least 2 prior systemic therapies. Accelerated approval was based on overall response rate and continued approval may be contingent upon confirmatory trials.
Please see full Prescribing Information including Boxed Warning.